PT  - JOURNAL ARTICLE
AU  - Sheppard, Rachel
AU  - Evanson, Benjamin
AU  - Campbell, Iona
AU  - Shand, Alan
TI  - Chronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: A case report of olmesartan-induced enteropathy
AID  - 10.1136/bcr-2023-255407
DP  - 2024 May 01
TA  - BMJ Case Reports
PG  - e255407
VI  - 17
IP  - 5
4099  - http://casereports.bmj.com/content/17/5/e255407.short
4100  - http://casereports.bmj.com/content/17/5/e255407.full
SO  - BMJ Case Reports2024 May 01; 17
AB  - Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.